Navigation Links
Watson Reaches Settlement with Teva Over Seasonale(R)
Date:5/7/2010

MORRISTOWN, N.J., May 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc. has reached a settlement with Teva Women's Health, Inc. on outstanding patent litigation related to Teva's Seasonale® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg) product.

On December 13, 2007, Teva filed a patent infringement lawsuit against Watson in the United States District Court for the District of New Jersey involving Watson's Quasense® product, which is a generic equivalent of Teva's Seasonale®.  Under terms of the settlement agreement, Teva has granted Watson a fully paid-up license to the U.S. patents covering Seasonale® and Watson will continue marketing its generic equivalent product Quasense® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg).  Watson further admits that the licensed patents are valid and enforceable.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson Confirms EVISTA(R) Patent Challenge
2. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 7th
3. Watson To Present at Bank Of America/Merrill Lynch 2010 Healthcare Conference
4. Watson Confirms Trilipix(R) Patent Challenge
5. Watson Confirms Rapamune(R) Patent Challenge
6. Watson Confirms Cenestin(R) Patent Challenge
7. Watson Says Appeals Court Affirms Concerta(R) Patent Invalid
8. Watson to Present at Barclays 2010 Global Healthcare Conference
9. Watson Receives FDA Approval for Generic Cardizem(R) LA
10. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
11. Watson Announces Actos(R) Patent Challenge Settlement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... DENVER , March 3, 2015  Tru-D ... at the Association for Perioperative Registered Nurses, Surgical ... Colorado , during Patient Safety Awareness Week ... with resources for safe clinical practice and professional ...   Photo - http://photos.prnewswire.com/prnh/20150302/178998LOGO   ...
(Date:3/3/2015)... 2015 Research and Markets ( ... Research,s new report "The Generic Drugs Market: ... Forecasts" to their offering. , ... usually intended to be interchangeable with an innovator ... the innovator company and marketed after the expiry ...
(Date:3/3/2015)... SAN DIEGO , March 3, 2015 /PRNewswire/ ... has exclusively licensed Pomaglumetad Methionil (mGlu2/3 receptor agonist), ... Company (NYSE:   LLY). Denovo gains all rights ... transfer of all intellectual property and other rights, ... re-acquire pomaglumetad upon a successful clinical trial, for ...
Breaking Medicine Technology:Tru-D SmartUVC to Exhibit Most Effective UV Disinfection Robot at AORN Surgical Conference and Expo 2015 2Tru-D SmartUVC to Exhibit Most Effective UV Disinfection Robot at AORN Surgical Conference and Expo 2015 3Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts' 2Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts' 3Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts' 4Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts' 5Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts' 6Denovo Biopharma Licenses Late-Stage Neuroscience Drug From Lilly For Development As A Personalized Medicine 2
... Shire plc (LSE: SHP, NASDAQ: ... the three months to March 31, 2012. ... Total revenues million +21% Non GAAP operating income $362 million ... diluted earnings per ADS $1.48 +20% US GAAP diluted earnings ...
... Inc. (Nasdaq: NBIX ) announced today that the ... the Nasdaq market closes on Wednesday,  May 2, 2012.  Neurocrine ... discuss its financial results and provide a Company update Wednesday ... p.m. Pacific Time). Participants can access the live ...
Cached Medicine Technology:Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 2Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 3Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 4Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 5Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 6Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 7Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 8Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 9Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 10Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 11Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 12Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 13Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 14Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 15Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 16Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 17Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 18Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 19Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 20Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 21Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 22Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 23Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 24Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 25
(Date:3/3/2015)... March 03, 2015 eMedEvents, a ... continuing medical education (CME) credit information, has officially ... doctors was initially launched in the United States ... its kind in the field of healthcare conference ... of this Denver, Colorado-based start-up company was successful ...
(Date:3/3/2015)... March 03, 2015 Venato, a ... announced that their flagship software solution now provides ... to be uploaded to the National Healthcare Safety ... Medicaid Services (CMS) require that hospitals submit healthcare ... no later than May 15 for each influenza ...
(Date:3/3/2015)... 2015 Volpara Solutions, leaders in the ... D. Pavlidis has joined their Board of Directors. ... executive management experience in the medical industry, including more ... organizations. , “John’s broad management experience in breast imaging ... be a tremendous asset to the sales, product marketing ...
(Date:3/3/2015)... Pass, OR (PRWEB) March 03, 2015 ... stroke severity* confirms what water advocate and radio host ... that dehydration – lack of sufficient water in the ... as much as 90 percent of the US population. ... dehydration is a factor in nearly all disease, including ...
(Date:3/3/2015)... T-System Inc. today announced the appointment ... as the company’s chief nursing officer along with a ... , “Today’s patients are demanding more immediate ... care and freestanding emergency centers one of the fastest ... chief executive officer. “We have a strong cross-functional ...
Breaking Medicine News(10 mins):Health News:eMedEvents Launches Online Medical Conference, Speaker and CME Platform in India 2Health News:Venato Incorporates Automated NHSN Reporting Tool to Their Software Solution 2Health News:Volpara Solutions Adds Medical Imaging Veteran John Pavlidis to Board of Directors 2Health News:Volpara Solutions Adds Medical Imaging Veteran John Pavlidis to Board of Directors 3Health News:Study linking dehydration and stroke severity supports fresh water advocate’s warnings 2Health News:Study linking dehydration and stroke severity supports fresh water advocate’s warnings 3Health News:T-System Renews Commitment to Clinically-Driven Innovation and Appoints Industry Leader as CNO 2Health News:T-System Renews Commitment to Clinically-Driven Innovation and Appoints Industry Leader as CNO 3
... MORE SERIOUS MENTAL ILLNESS, ... NEW REPORT REVEALS ... 9 Millions of American teens report,experiencing weeks of hopelessness and loss ... using marijuana and other,drugs, making their situation worse, according to a new ...
... of Leicester is leading on a national study to ... been announced today. , Professor Terry Brugha, Professor of ... the study in conjunction with a team of research ... (NatCen), Research Autism and Professor Simon Baron-Cohen of the ...
... May 9 Oceana, an international,ocean conservation group based ... for many years. Consuming big fish high on,the food ... to mercury, a heavy,metal that can cause neurological and ... Oceana celebrity spokes-Mom Amber Valletta,offers a few tips for ...
... in fried foods, snacks, coffee upped chances of disease ... large amounts of acrylamide, a chemical commonly found in ... raise the risk of kidney cancer, especially in smokers, ... of a positive association between dietary acrylamide intake and ...
... New Technologies in Surface and Volume ... ... ANSYS, Inc. (Nasdaq:,ANSS), a global innovator of simulation software and technologies ... of its TGrid(TM) advanced mesh generation software. TGrid,technology is a specialized ...
... 9, 2008 More than 4,000 infection prevention ... expected to convene at a five-day conference next ... facing their profession today. , Strategies for infection ... healthcare-associated infections (HAIs) and emerging multidrug-resistant bacteria are ...
Cached Medicine News:Health News:White House Office of National Drug Control Policy National Youth Anti-Drug Media Campaign 2Health News:White House Office of National Drug Control Policy National Youth Anti-Drug Media Campaign 3Health News:University of Leicester to lead audit of adults with autism 2Health News:University of Leicester to lead audit of adults with autism 3Health News:Amber Valletta on Preventing Mercury Exposure 2Health News:Amber Valletta on Preventing Mercury Exposure 3Health News:Acrylamide Raises Kidney Cancer Risk 2Health News:Acrylamide Raises Kidney Cancer Risk 3Health News:TGrid 5.0 Advances Automatic, High-Quality Meshing Tools for Increased Productivity 2Health News:TGrid 5.0 Advances Automatic, High-Quality Meshing Tools for Increased Productivity 3Health News:APIC conference to focus on patient safety and 'Targeting Zero' initiatives to reduce HAIs 2
... Designed with 96-well plates in ... useful for molecular biology applications: PCR* ... 96-well plates, etc. Used with Diamond ... system, this product will maximize performance ...
... variety of applications. • Whole pipette is autoclavable ... rotated against the handle to work in a ... towards the microtiter plate. • The special nose ... pipette tips, and provides a firm, parallel fit. ...
... Features and Benefits: 1-12channel pipette ... new product number, created to ... If showing no availability yet, ... Sigma-Aldrich number (Z37,173-4) or contact ...
... 96-well plates in mind, Pipetman Ultra ... biology applications: PCR* sequencing, immunology assays, ... Used with Diamond Tips from Gilson's ... will maximize performance and assure productivity.,* ...
Medicine Products: